Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Researchers find new pathway that leads to brain cell death in neurodegenerative disorders

Researchers find new pathway that leads to brain cell death in neurodegenerative disorders

Aptuit announces strategic partnership Siena Biotech

Aptuit announces strategic partnership Siena Biotech

Scientists identify new targets to develop treatment for HD

Scientists identify new targets to develop treatment for HD

Scientists study mutant protein lump formation process to control brain cell death

Scientists study mutant protein lump formation process to control brain cell death

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

Prevalence of HD substantially underestimated in the UK

Prevalence of HD substantially underestimated in the UK

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

Traumatic brain injuries during war increase risk of epilepsy even decades later

Traumatic brain injuries during war increase risk of epilepsy even decades later

Scientists identify new strategy for treating movement disorders

Scientists identify new strategy for treating movement disorders

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Neuralstem announces completion of $10 million registered direct offering

Neuralstem announces completion of $10 million registered direct offering

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Update on Regulus and sanofi-aventis collaboration

Update on Regulus and sanofi-aventis collaboration

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.